FDA approves 1st targeted drug for certain leukemia patients
April 28, 2017
U.S. regulators Friday approved the first targeted drug for certain patients with an aggressive form of leukemia.
The Food and Drug Administration approved the drug for adults with acute myeloid leukemia, or AML, who have a genetic mutation called FLT3. Also OK'd was a test to identify those patients. The drug, Rydapt, known chemically as midostaurin, is used along with chemotherapy.
"Prior to the approval of midostaurin, the treatment of AML had been relatively unchanged for more than 25 years," Dr. Richard Stone of Dana-Farber Cancer Institute in Boston, said in a statement. He led testin...